AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 DEC 10 - (NewsRx.com & NewsRx.net) -- Scientists have modeled a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques.
According to a study from an international team of researchers, "We have modeled smallpox vaccination with Dryvax (Wyeth) in rhesus macaques that had depletion of CD4+ T cells induced by infection with simian immunodeficiency virus or simian/human immunodeficiency virus. Smallpox vaccination induced significantly larger skin lesions in immunocompromised macaques than in healthy macaques. Unexpectedly, 'progressive vaccinia' was infrequent."
"Vaccination of immunocompromised macaques with the genetically-engineered, replication-deficient poxvirus NYVAC, before or after retrovirus infection, was safe and lessened the severity of Dryvax-induced skin lesions," stated Yvette Edghill-Smith at the National Cancer Institute in the United States and collaborators around the world. "Neutralizing antibodies to vaccinia were induced by NYVAC, even in macaques with severe CD4+ T cell depletion, and their titers inversely correlated with the time to complete resolution of the skin lesions."
"Together, these ...
Source: HighBeam Research, Safer smallpox vaccination regimen modeled for HIV-1-infected...